Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk
in type 1 diabetes (T1D). Non-esterified fatty acid elevation is a significant contributor to
IR in T1D and may be a target of intervention. The hypothesis of the study is that isolated
fatty acid lowering with acipimox will improve insulin action and blood vessel function and
have the benefit of reducing mitochondrial oxidant generation and improving mitochondrial
function in T1D. Targeting IR through fatty acid lowering is a novel approach to T1D
treatment that may significantly improve current management of TID and of cardiovascular
disease (CVD) risk in this high risk population.